The BET inhibitors, like the novel GS-5829, target CLL cells, inducing apoptosis via disrupting signaling pathways of MYC, BLK, AKT, and ERK1/2 [544]. This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.